Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...
Under its terms, those products will be sold by their developers through a planned national online drug platform called TrumpRx at a steep discount to certain current rates (under agreements set with ...
The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...
Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.
In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...
The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...
Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...
US accounts for 72.7% of the MSCI World Index, compared with just 2.6% for Europe’s biggest stock market, France ...
After a rapid rise, Eli Lilly needs only an 11% gain to hit $1 trillion in market value. Revenue is expected to rise 26% next ...
Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback